A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
Acute Respiratory Distress Syndrome (ARDS) patients will be randomized to receive either IC14 (a single dose of 4 mg/kg followed by 2 mg/kg on Days 2-4) or placebo. Study participation will be for a total of 28 days.
Epistemonikos ID: 6532c05e52624bb6f3bca96b8c14d740acd206c2
First added on: May 20, 2024